Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer.
- Author:
Woo Sung HONG
1
;
Ja Young JEON
;
Seok Yun KANG
;
Yong Sik JUNG
;
Ji Young KIM
;
Mi Sun AHN
;
Doo Kyoung KANG
;
Tae Hee KIM
;
Hyun Ee YIM
;
Young Sil AN
;
Rae Woong PARK
;
Ku Sang KIM
Author Information
- Publication Type:Original Article
- Keywords: Breast neoplasms; Neoadjuvant therapy
- MeSH: Breast; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fever; Humans; Mastectomy, Segmental; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Polymerase Chain Reaction; Receptor, Epidermal Growth Factor; Receptor, erbB-2; Taxoids
- From:Journal of the Korean Surgical Society 2013;85(1):7-14
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Neoadjuvant chemotherapy is the standard treatment for patients with locally advanced breast cancer and is increasingly considered for patients with operable disease. Recently, as many clinical trials have demonstrated favorable outcomes of anthracycline-taxane based regimen, this approach has been widely used in the neoadjuvant setting. METHODS: We compared women who received adriamycine and docetaxel (AD) with adriamycin, cyclophosphamide followed by paclitaxel (AC-T) as neoadjuvant chemotherapy. The AD group was scheduled for six cycles of AD (50 mg/m2 and 75 mg/m2, respectively) at a 3-week interval. The AC-T group was scheduled for four cycles of adriamycin and cyclophosphamide (50 mg/m2 and 500 mg/m2, respectively) followed by four cycles of paclitaxel (175 mg/m2) at a 3-week interval. RESULTS: The responses of chemotherapy were equivalent (overall response rate [AD, 75.7% vs. AC-T, 80.9%; P = 0.566], pathologic complete response [pCR] rate [breast and axilla: AD, 10.8% vs. AC-T, 12.8%; P = 1.000; breast only: AD, 18.9% vs. AC-T, 14.9%, P = 0.623], breast conserving surgery rate [P = 0.487], and breast conserving surgery conversion rate [P = 0.562]). The pCR rate in the breast was higher in the human epidermal growth factor receptor 2 (HER2) positive cases (HER2 positive 33.3% vs. negative 10%, P = 0.002). Although nonhematologic toxicities were comparable, hematologic toxicities were more severe in the AD group. Most women in the AD group suffered from grade 3/4 neutropenia (P < 0.001) and neutropenic fever (P < 0.001). CONCLUSION: Tumor responses were not different in various variables between the two groups. However, AC-T was a more tolerable regimen than AD in patients with breast cancer receiving neoadjuvant chemotherapy.
